Request Your Free Trend Report Now:

"Inside the Business Strategies of Big Pharma"

Explore how industry leaders are adapting and evolving their strategies in this Trendline.

Large pharma faces growing challenges, from looming patent cliffs and heightened FTC scrutiny on M&A to regulatory shifts like Medicare price negotiations and new trade tariffs. In response, they are refining strategies by prioritizing lower-risk pipeline investments, optimizing R&D, and maximizing the value of existing drugs through new delivery methods and expanded indications.

INCLUDED IN THIS TRENDLINE

• With uncertainty roiling Big Pharma, execs are placing lower-risk bets
• Merck, Lilly launch manufacturing R&D consortium to help ‘bolster’ U.S. production
• Will 2025 mark pharma’s pivot to bigger deals after years of lackluster M&A?

Offered Free by: PharmaVoice and Thermo Fisher Scientific
See All Resources from: PharmaVoice and Thermo Fisher Scientific